IRIS UniCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.718
NA - Nord America 2.599
AS - Asia 1.400
SA - Sud America 338
AF - Africa 44
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.535
IT - Italia 881
SG - Singapore 594
SE - Svezia 555
CN - Cina 370
BR - Brasile 301
DE - Germania 252
IE - Irlanda 246
FR - Francia 202
ID - Indonesia 113
FI - Finlandia 94
GB - Regno Unito 87
RU - Federazione Russa 87
KR - Corea 65
IN - India 61
NL - Olanda 53
CA - Canada 38
AT - Austria 37
HK - Hong Kong 34
TR - Turchia 34
CZ - Repubblica Ceca 29
BE - Belgio 27
ES - Italia 23
IR - Iran 23
UA - Ucraina 23
PL - Polonia 21
CH - Svizzera 19
JP - Giappone 16
CI - Costa d'Avorio 14
RO - Romania 14
MK - Macedonia 13
PA - Panama 13
IL - Israele 12
PH - Filippine 12
RS - Serbia 11
EG - Egitto 10
AR - Argentina 9
LT - Lituania 9
MA - Marocco 9
MX - Messico 8
BD - Bangladesh 7
IQ - Iraq 7
PE - Perù 7
PT - Portogallo 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
PK - Pakistan 5
DK - Danimarca 4
LK - Sri Lanka 4
NZ - Nuova Zelanda 4
PY - Paraguay 4
VE - Venezuela 4
VN - Vietnam 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BG - Bulgaria 3
CL - Cile 3
GR - Grecia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
BT - Bhutan 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EE - Estonia 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
SA - Arabia Saudita 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GL - Groenlandia 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
NP - Nepal 1
QA - Qatar 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.109
Salva come PNG Salva come JPEG
Città #
Chandler 588
Singapore 385
Ashburn 341
Dublin 217
Rome 191
New York 170
Milan 139
Jakarta 113
Helsinki 67
Hefei 64
Marseille 64
Seoul 64
Boston 58
Princeton 58
Los Angeles 57
San Mateo 56
Moscow 46
Frankfurt am Main 39
Nuremberg 36
Düsseldorf 35
Wilmington 33
Palermo 31
The Dalles 31
Munich 30
Bremen 28
Beijing 27
Chicago 27
Hong Kong 27
London 25
Nanjing 25
São Paulo 24
Ann Arbor 22
Brussels 21
Dearborn 21
Brno 20
Boardman 19
Toronto 19
Fairfield 18
Pune 18
Columbus 17
Falkenstein 17
Vienna 16
Houston 15
Kish 15
Turin 15
Abidjan 14
Redmond 14
Seattle 14
Paris 13
Andover 12
Cattolica 12
Redwood City 12
Washington 12
Florence 11
Hyderabad 11
Lauterbourg 11
Menlo Park 11
Portsmouth 11
Augusta 10
Belo Horizonte 10
Ottawa 10
Salamanca 10
Shanghai 10
Skopje 10
Turku 10
Bologna 9
Brasília 9
Busto Arsizio 9
Changsha 9
Council Bluffs 9
Jinan 9
Lancaster 9
Santa Clara 9
Tokyo 9
Bari 8
Lappeenranta 8
Naples 8
Norwalk 8
San Francisco 8
Stockholm 8
Woodbridge 8
Amsterdam 7
Cairo 7
Guangzhou 7
Hebei 7
Istanbul 7
Jacksonville 7
Rio de Janeiro 7
Roubaix 7
Secaucus 7
Shenzhen 7
Leawood 6
Lima 6
Nanchang 6
Niš 6
North Bergen 6
Salvador 6
Ankara 5
Bexley 5
Brescia 5
Totale 3.835
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 234
Performance of Upper Limb module for Duchenne muscular dystrophy 168
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 131
Revised upper limb module for spinal muscular atrophy: Development of a new module 110
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 105
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 102
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 100
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 100
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 92
Developmental milestones in type I spinal muscular atrophy 91
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 89
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 86
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 86
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 85
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 85
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 84
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 84
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 84
Assessing floppy infants: a new module 84
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 83
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 83
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 81
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 80
Developmental milestones in type I spinal muscular atrophy 79
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 79
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 77
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 77
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 76
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 76
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 76
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 75
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 74
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 74
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 74
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 73
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 73
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 72
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 69
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 68
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 67
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 67
Longitudinal natural history in young boys with Duchenne muscular dystrophy 67
Clinical Variability in Spinal Muscular Atrophy Type III. 65
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 65
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 64
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 63
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 63
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 62
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 61
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 61
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 60
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 60
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 60
Development of an academic disease registry for spinal muscular atrophy 60
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 60
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 60
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 60
Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. 59
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. 58
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 57
Revised upper limb module for spinal muscular atrophy: Development of a new module 56
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 55
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 55
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 54
Language Development in Preschool Duchenne Muscular Dystrophy Boys 53
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 53
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 53
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 52
Risdiplam in Type 1 Spinal Muscular Atrophy 52
Language Development in Preschool Duchenne Muscular Dystrophy Boys 52
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 52
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 52
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 51
Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy 51
Revised upper limb module for spinal muscular atrophy: 12 month changes 51
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 50
Sleep disorders in spinal muscular atrophy 49
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 49
Development of an International SMA Bulbar Assessment for Inter-professional Administration 48
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 48
Longitudinal natural history of type I spinal muscular atrophy: A critical review 48
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 46
Gain and loss of abilities in type II SMA: A 12-month natural history study 46
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 46
Early treatment of type II SMA slows rate of progression of scoliosis 45
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 45
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 44
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 44
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 43
First international workshop on rehabilitation management and clinical outcome measures for spinal muscular atrophy 42
Long term follow-up of scoliosis progression in type II SMA patients 41
An observational study of functional abilities in infants, children, and adults with type 1 SMA 41
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 41
An observational study of functional abilities in infants, children, and adults with type 1 SMA 40
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 38
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 38
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 38
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 37
An observational study of functional abilities in infants, children, and adults with type 1 SMA 34
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study 34
Totale 6.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202046 0 0 0 0 0 0 0 0 0 0 44 2
2020/202164 1 7 3 3 11 2 4 1 9 7 15 1
2021/2022693 45 7 15 92 52 27 17 95 50 41 122 130
2022/20232.008 179 244 122 269 135 256 143 177 273 37 101 72
2023/20241.655 60 295 70 139 76 293 195 83 42 85 130 187
2024/20252.565 64 53 215 197 246 167 165 134 424 251 649 0
Totale 7.259